Ask Warren

EuBiologics

206650 · KOSDAQ · ₩206650 · 유바이오로직스

₩7,500▲ ₩40 (0.54%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩33B₩16B₩32B₩41B₩36B₩40B₩37B₩36B
Cost of sales₩17B₩7.1B₩11B₩16B₩19B₩18B₩15B₩14B
Gross profit₩16B₩8.5B₩21B₩25B₩17B₩22B₩22B₩22B
Operating income₩8.6B₩2.2B₩14B₩19B₩11B₩17B₩17B₩17B
Net income₩7.5B₩3.7B₩414M₩17B₩7.7B₩16B₩8.2B₩16B
Net income to shareholders₩7.5B₩3.7B₩414M₩17B₩7.7B₩16B₩8.2B₩16B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩239B₩235B₩240B₩233B₩224B₩218B₩202B₩175B
Current assets₩140B₩135B₩137B₩119B₩106B₩99B₩83B₩60B
Cash and equivalents₩14B₩21B₩24B₩24B₩25B₩18B₩23B₩12B
Total liabilities₩58B₩55B₩65B₩59B₩68B₩70B₩70B₩51B
Current liabilities₩35B₩34B₩42B₩33B₩42B₩44B₩43B₩30B
Borrowings₩17B₩16B₩0₩14B₩14B₩6B₩8.5B₩12B
Total equity₩182B₩180B₩175B₩174B₩156B₩148B₩132B₩124B
Shareholders' equity₩182B₩180B₩175B₩174B₩156B₩148B₩132B₩124B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩5.5B₩2.8B₩5.6B₩20B₩6.9B₩17B₩31B₩7.9B
Capital spending₩629M₩381M₩9.4B−₩879M−₩1.6B−₩1.4B−₩1.1B−₩1.6B
Free cash flow−₩6.1B₩2.4B−₩3.8B₩19B₩5.3B₩16B₩30B₩6.3B

Consolidated where available. Amounts in won.

Also known as: EuBiologics / 유바이오로직스 / 206650 / KRX:206650

Source: KRX statistical information